Trispecific blockade of IL-4/IL-13 and upstream TSLP is intended to broaden type 2 inflammatory pathway coverage and potentially enhance durability versus single-axis inhibition. Week-16 EASI 75 rates ...
The National Eczema Association (NEA) has released the State of AD 2026 National Indicator Report, a Milliman analysis ...
Without a formal staging system, advanced basal cell carcinoma is defined by the interplay of tumor size, anatomic site, depth, histology, and host factors that may not be apparent on initial biopsy.
Dr. Singh describes hedgehog pathway inhibitors as a frequent first-line option for patients with locally advanced basal cell carcinoma. Speaking as a Mohs surgeon, he nonetheless believes the class ...
Nearly 95% of assessed TikTok “glass skin” videos contained potentially misleading claims, with none citing external references and none produced by dermatologists.
Nemolizumab (Nemluvio) maintained improvements in skin lesions, itch, sleep disturbance, and quality of life through 3 years in adults and adolescents with moderate to severe atop ...
New data presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress highlight the effects of ...
ILT7 is selectively expressed on plasmacytoid dendritic cells, and daxdilimab binding is intended to reduce pDCs in tissue ...
EPP arises from reduced ferrochelatase activity and excess protoporphyrin made largely in the bone marrow. Accurate diagnosis ...
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
Baricitinib (Olumiant) is FDA-approved for pediatric patients 12 years of age and older with severe alopecia areata, in ...
The panel reviews years of efficacy and safety data behind today's approved HS biologics. "Long-Term Efficacy and Safety Data for HS Biologics" takes up the clinical trial evidence behind adalimumab, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results